Evolution of artificial cells using nanobiotechnology of hemoglobin based RBC blood substitute as an example

Artificial Cells, Blood Substitutes, and Biotechnology

Volumn 34, Issue 6, 2006, Pages 551-566

  Chang, Thomas Ming Swi ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Antioxidants; Artificial cells; Blood substitutes; Catalase; Hemoglobin; Nanobiotechnology; Nanoencapsulation; Oxygen radicals; Polyethylene glycol; Polyhemoglobin; Polylactide; Superoxide dismutase

Indexed keywords

ANTIOXIDANTS; BLOOD SUBSTITUTES; CELL CULTURE; HEMOGLOBIN; NANOSTRUCTURED MATERIALS; POLYETHYLENE GLYCOLS;

NANOBIOTECHNOLOGY; NANOENCAPSULATION; POLYHEMOGLOBIN; POLYLACTIDES; SUPEROXIDE DISMUTASE;

BIOTECHNOLOGY;

ANTIOXIDANT; ARTIFICIAL BLOOD; BLOOD SUBSTITUTE; CELL ENZYME; COPOLYMER; HEMOGLOBIN; MONOPHENOL MONOOXYGENASE; OXYGEN; POLYMER; POLYMERIZED HEMOGLOBIN; RECOMBINANT HEMOGLOBIN; TETRAMER;

ANTIOXIDANT ACTIVITY; BIODEGRADABILITY; BIOTECHNOLOGY; BLEEDING; BLOOD DONOR; BLOOD VESSEL REACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CONJUGATION; CROSS LINKING; ERYTHROCYTE; HUMAN; LIPID MEMBRANE; LIPID VESICLE; MEDICAL RESEARCH; NANOPARTICLE; NANOTECHNOLOGY; NONHUMAN; OXYGEN TRANSPORT; POLYMERIZATION; PRESSOR RESPONSE; VASOCONSTRICTION;

ANTIOXIDANTS; BLOOD SUBSTITUTES; HEMOGLOBINS; HUMANS; NANOTECHNOLOGY; RECOMBINANT PROTEINS; VASOCONSTRICTOR AGENTS;

EID: 33750870089     PISSN: 10731199     EISSN: 15324184     Source Type: Journal    
DOI: 10.1080/10731190600973808     Document Type: Conference Paper

References (48)

1. Chang, T.M.S. (1957). "Hb Corpuscles." Report of a research project for Honours Physiology, Medical Library, McGill University.
2. Also reprinted as part of "30 Anniversary in Artificial Red Blood Cells Research." J. Biomaterials, Artificial Cells & Artificial Organs 16: 1-9.
3. Chang, T.M.S. (1964). Semipermeable microcapsules. Science 146(3643): 524.
4. Chang, T.M.S. (1965). Ph.D. Thesis, McGill University.
5. Chang, T.M.S. (1972). Artificial cells. Monograph. Charles C. Thomas, Springfield, IL (full text available for free online viewing at www.artcell. mcgill.ca).
6. Chang, T.M.S. (1975). Microencapsulated adsorbent hemoperfusion for uremia, intoxication and hepatic failure. Kidney Int. 7: S387-S392.
7. Winchester, J.F. (1988). Hemoperfusion, in Replacement of Renal Function by Dialysis, J.F. Maher, Ed., Kluwer Academic Publisher: Boston, pp. 439-592.
8. Chang, T.M.S. (1976). Biodegradable semipermeable microcapsules containing enzymes, hormones,vaccines, and other biologicals. J. Bioengineering 1: 25-32.
9. Chang, T.M.S. (1991). Artificial cells, in Encyclopedia of Human Biology, Renalo Dulbecco, Ed., Volume 1, Academic Press, Inc.: San Diego, CA, pp. 377-383.
10. Chang, T.M.S. (2005). Therapeutic applications of polymeric artificial cells. Nature Review: Drug Discovery 4: 221-235.
11. Liu, Z.C., Chang, T.M.S. (2006). Transdifferentiation of bioencapsulated bone marrow cells into hepatocyte-like cells in the 90% hepatectomized rat model. Journal of Liver Transplantation 12: 566-572.
12. Orive, G., Hernandez, R.M., Gascon, A.R., Calafiore, R., Chang, T.M.S. et al. (2003). Cell encapsulation: promise and progress. Nature Medicine 9: 104-107.
13. Chang, T.M.S. (2006). Blood substitutes based on bionanotechnology. Trends in Biotechnology 24: 72-377.
14. Chang, T.M.S. (1971). Stabilization of enzyme by microencapsulation with a concentrated protein solution or by crosslinking with glutaraldehyde. Biochem Biophys. Res Com. 44: 1531-1533.
15. Gould, S.A., Sehgal, L.R., Sehgal, H.L., DeWoskin, R., Moss, G.S. (1998). The clinical development of human polymerized Hb, in Blood Substitutes: Principles, Methods, Products and Clinical Trials, T.M.S. Chang, Ed., Vol. 2, Karger, pp. 12-28.
16. Gould, S.A. et al. (2002). The life-sustaining capacity of human polymerized Hb when red cells might be unavailable. J. Am. Coll. Surg. 195: 445-452.
17. Sprung, J., Kindscher, J.D., Wahr, J.A., Levy, J.H., Monk, T.G., Moritz, M.W., O'Hara, P.J. (2002). The use of bovine Hb glutamer-250 (Hemopure) in surgical patients: Results of a multicenter, randomized, single-blinded trial. Anesth Analg 94(4): 799-808.
18. Pearce, L.B., Gawryl, M.S., Rentko, V.T., Moon-Massat, P.F., Rausch, C.W. (2006). HBOC-201 (Hb Glutamer-250 (bovine), hemopure): clinical studies, in Blood Substitutes, R. Winslow, Ed., Academic Press: San Diego, pp. 437-450.
19. Lok, C. (2001). Blood product from cattle wins approval for use in humans. Nature 410(6831): 855.
20. Li, T., Yu, R., Zhang, H.H., Liang, W.G., Yang, X.M., Yang, C.M. (2006). A method for purification and viral inactivation of human placenta Hb. Artificial Cells, Blood Substitutes and Biotechnology 34: 175-188.
21. Wong, J.T. (1988). Rightshifted dextran Hb as blood substitute. Biomaterials, Artificial Cells and Artificial Organs 16: 237-245.
22. Shorr, R.G., Viau, A.T., Abuchowski, A. (1996). Phase 1B safety evaluation of PEG Hb as an adjuvant to radiation therapy in human cancer patients. Artficial Cells, Blood Substitutes and Immobilization Biotechnology 24: 407.
23. Iwashita, Y., Yabuki, A., Yamaji, K., Iwasaki, K., Okami, T., Hirati, C., Kosaka, K. (1988). A new resuscitation fluid "Stabilized Hb" preparation and characteristics. Biomaterials, Artificial Cells and Artificial Organs 16: 271-280.
24. Winslow, R. (2006). Blood Substitutes, Academic Press: San Diego.
25. Nelson, D.J. (1998). Blood and HemAssistTM (DCLHb): Potentially a complementary therapeutic team, in Blood Substitutes: Principles, Methods, Products and Clinical Trials, T.M.S. Chang, Ed., Vol. 2, Karger: Basel, pp. 39-57.
26. Burhop, K.E., Estep, T.E. (2001). Hb induced myocardial lesions. Artf. Cells Blood Subst. Immob Biotech. 29: 101-106.
27. Fronticelli, C., Bellelli, A., Briniger, W.S. (2004). Approach to the engineering of Hb based oxygen carrier. Transfusion Mediciner 5: 516-520.
28. Olsen, J.S., Foley, E.W., Rogge, C. (2004). Nitric oxide scavenging and the hypertensive effect of Hb-based blood substitutes. Free Radic. Biol. Med. 36: 685-697.
29. Alayash, A.I. (2004). Oxygen therapeutics: Can we tame Hb. Nature Rev. Drug Discov. 3: 152-159.
30. Chang, T.M.S. (1997). Blood Substitutes: Principles, Methods, Products and Clinical Trials. Vol.1, Karger, Basel (full text available for free online viewing at www.artcell.mcgill.ca).
31. De Angelo, J. (1999). Nitric oxide scavengers in the treatment of shock associated with systemic inflammatory response syndrome. Exp. Opin. Pharmacother 1: 19-29.
32. Doherty, D.H., Doyle, M.P., Curry, S.R., Vali, R.J., Fattor, T.J., Olson, J.S., Lemon, D.D. (1998). Rate of reaction with nitric oxide determines the hypertensive effect of cell-free Hb. Nature Biotechnology 16: 672-676.
33. Matheson, B., Kwansa, H.E., Rebel, A., Bucci, E. (2002). Vascular responses to infusions of a non-extravasating Hb polymer. J. Appl. Physiol. 93: 1479-1486.
34. Tsai, A., Vandegriff, K., Intaglietaa, M., Winslow, R. (2003). Targeted oxygen delivery by cell-free Hb: a new basis for oxtgen therapeutics. Am. J. Physiol. 285: H1411-H1419.
35. Yu, B.L., Liu, Z.C., Chang, T.M.S. (2006). PolyHb with different percentage of tetrameric Hb and effects on vasoactivity and electrocardiogram. Artificial Cells, Blood Substitutes & Biotechnology 34: 159-174.
36. D'Agnillo, F., Chang, T.M.S. (1998). PolyHb-superoxide dismutase. Catalase as a blood substitute with antioxidant properties. Nature Biotechnology 16(7): 667-671.
37. Chang, T.M.S., D'Agnillo, F., Razack, S. (1998). A second generation Hb based blood substitute with antioxidant activities, in Blood Substitutes: Principles, Methods, Products and Clinical Trials, T.M.S. Chang, Ed., Karger: Basel, Vol. 2, pp. 178-186.
38. Powanda, D., Chang, T.M.S. (2002). Cross-linked polyHb-superoxide dismutase-catalase supplies oxygen without causing blood brain barrier disruption or brain edema in a rat model of transient global brain ischemia-reperfusion. Artificial Cells, Blood Substitutes & Immob. Biotechnology 30: 25-42.
39. Buehler, P.W., Mehendale, S., Wang, H., Xie, J., Ma, L., Trimble, C.E., Hsia, C.J., Gulati, A. (2000). Resuscitative effects of polynitroxylated alpha-alpha-cross-linked Hb following severe hemorrhage in the rat. Free Radic Biol Med. 29(8): 764-774.
40. Yu, B.L., Chang, T.M.S. (2004). In vitro and in vivo effects of polyHb-tyrosinase on murine B16F10 melanoma. Melanoma Res. 14: 197-202.
41. Chang, T.M.S., Poznansky, M.J. (1968). Semipermeable microcapsules containing catalase for enzyme replacement in acatalsaemic mice. Nature 218(5138): 242-245.
42. Rudolph, A.S., Rabinovici, R., Feuerstein, G.Z. (1997). Red Blood Cell Substitutes: Basic Principles and Clinical Applications, Marcel Dekker, Inc.: New York.
43. Philips, W.T., Klepper, R.W., Awasthi, V.D., Rudolph, A.S., Cliff, R., Kwasiborski, V.V., Goins, B.A. (1999). Polyethylene glyco-modified liposome-encapsulated Hb: a long circulating red cell substitute. J. Pharm. Exp. Therapeutics 288: 665-670.
44. Tsuchida, E., Komatsu, T., Yanagimoto, T., Sakai, H. (2002). Preservation stability and in vivo administration of albumin-heme hydrid solution as an entirely synthetic oxygen-carrier. Polymer Adv. Technol. 13: 845-850.
45. Kobayashi, K., Tsuchida, E., Horinouchi, H. (2005). Artificial Oxygen Carriers, Springer Verlag: New York.
46. Yu, W.P., Chang, T.M.S. (1996). Submicron polymer membrane Hb nanocapsules as potential blood substitutes: preparation and characterization. Artificial Cells, Blood Substitutes & Immobilization Biotechnology 24: 169-184.
47. Chang, T.M.S., Yu, W.P. (1998). Nanoencapsulation of Hb and rbc enzymes based on nanotechnology and biodegradable polymer, in Blood Substitutes: Principles, Methods, Products and Clinical Trials, T.M.S. Chang, Ed., Karger: Basel, Vol. 2, pp. 216-231.
48. Chang, T.M.S., Powanda, D., Yu, W.P. (2003). Ultrathin polyethylene-glycol-polylactide copolymer membrane nanocapsules containing polymerized Hb and enzymes as nano-dimension red blood cell substitutes. Artificial Cells, Blood Substitutes & Biotechnology 31(3): 231-248.